852
Participants
Start Date
April 24, 2019
Primary Completion Date
May 2, 2024
Study Completion Date
May 31, 2025
SYD-101 Dose 1
Sterile topical ophthalmic solution
SYD-101 Dose 2
Sterile topical ophthalmic solution
Vehicle
Sterile topical ophthalmic solution without active ingredient
Site 205, Vienna
Site 203, Linz
Site 204, Graz
Site 127, Buffalo
Site 128, Cranberry Township
Site 113, Virginia Beach
Site 117, Chapel Hill
Site 121, Raleigh
Site 108, Charleston
Site 124, Marietta
Site 119, Sweetwater
Site 122, Fort Lauderdale
Site 120, Tamarac
Site 109, Jupiter
Site 135, Indianapolis
Site 131, Munster
Site 105, Fargo
Site 106, Wilmette
Site 116, Chicago
Site 114, Washington
Site 137, Pittsburg
Site 115, The Woodlands
Site 142, San Antonio
Site 101, San Antonio
Site 126, Lakeway
Site 100, Fort Collins
Site 130, Colorado Springs
Site 149, Ogden
Site 140, Ogden
Site 139, Albuquerque
Site 132, Henderson
Site 144, Pasadena
Site 200, Trenčín
Site 143, Irwindale
Site 148, San Diego
Site 104, San Diego
Site 110, Santa Barbara
Site 133, Sunnyvale
Site 147, Tigard
Site 111, Medford
Site 102, Danbury
Site 150, Waterbury
Site 138, Bangor
Site 123, Boston
Sie 136, Bala-Cynwyd
Site 202, Bratislava
Site 201, Trebišov
Sydnexis, Inc.
INDUSTRY